Abstract | BACKGROUND:
T900607 is a novel tubulin active agent which disrupts microtubule polymerization by a unique mechanism of action. This phase I trial was conducted to determine the maximum tolerated dose, recommended phase II dose, pharmacokinetic properties and toxicities of this agent. PATIENTS AND METHODS: Patients with advanced and/or metastatic solid malignancies were enrolled, for an open dose escalation of T900607 administered intravenously over 30 minutes every 21-days. RESULTS: Thirty patients were enrolled on 7 dose levels ranging from 15 to 270 mg/m(2). No DLTs were seen until 270 mg/m(2), the sixth dose level, with 1 patient experiencing Grade 3 thrombocytopenia, 1 grade 4 troponin increase and 1 grade 5 myocardial infarction in an expanded cohort of 6 patients. The dose was decreased to 180 mg/m(2) with increased cardiac monitoring and at this dose 3/4 patients experienced cardiac toxicity. Further animal cardiotoxicity studies failed to reveal any cardiac effects and the study was reopened at 130 mg/m(2); of 6 enrolled patients, 1 had grade 3 drug related lethargy considered to be a DLT and this dose was considered the RP2D. No objective responses were seen but stable disease was reported in 7/20. Pharmacokinetic analysis showed that AUC and C(max) increased with dose with considerable intrapatient variability, a short half life of < 1 hour, and no apparent dose dependency clearance. CONCLUSIONS:
|
Authors | Karen A Gelmon, Karl Belanger, Denis Soulieres, Carolyn Britten, Stephen Chia, Danielle Charpentier, Kim Chi, Jean Powers, Wendy Walsh, Lesley Seymour |
Journal | Investigational new drugs
(Invest New Drugs)
Vol. 23
Issue 5
Pg. 445-53
(Oct 2005)
ISSN: 0167-6997 [Print] United States |
PMID | 16133796
(Publication Type: Clinical Trial, Phase I, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antineoplastic Agents
- Sulfonamides
- T 900607
|
Topics |
- Adult
- Aged
- Antineoplastic Agents
(administration & dosage, adverse effects, pharmacokinetics)
- Fatigue
(chemically induced)
- Female
- Heart
(drug effects, physiology)
- Humans
- Male
- Middle Aged
- Nausea
(chemically induced)
- Neoplasms
(drug therapy, metabolism)
- Sulfonamides
(administration & dosage, adverse effects, pharmacokinetics)
- Thrombocytopenia
(chemically induced)
- Vomiting
(chemically induced)
|